Literature DB >> 3102281

Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption.

R C Percival, G H Urwin, S Harris, A J Yates, J L Williams, M Beneton, J A Kanis.   

Abstract

We have investigated the hypothesis that carcinoma of the prostate with skeletal metastases is associated with increased bone resorption. In 54 affected patients a close correlation was observed between serum activity of alkaline phosphatase and urinary excretion of hydroxyproline (r = +0.818; P less than 0.001), comparable to that seen in Paget's disease of bone. The administration of synthetic salmon calcitonin (100 U subcutaneously) induced a significant fall in serum calcium and urinary excretion of hydroxyproline, proportional to the prevailing rate of bone turnover, as assessed by serum alkaline phosphatase or hydroxyprolinuria. Administration of the diphosphonate, etidronate, also decreased hydroxyprolinuria, suggesting that urinary hydroxyproline reflected increased rates of bone resorption in this disorder. Histology of bone in sites adjacent to and distant from skeletal metastases showed increased histological indices of bone resorption. These results suggest that the skeletal disease associated with prostatic carcinoma is characterized by generalized increases in bone resorption as well as focal increases in bone formation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3102281

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  20 in total

1.  Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue.

Authors:  Zhong Dong; R Daniel Bonfil; Sreenivasa Chinni; Xiyun Deng; J Carlos Trindade Filho; Margarida Bernardo; Ulka Vaishampayan; Mingxin Che; Bonnie F Sloane; Shijie Sheng; Rafael Fridman; Michael L Cher
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

Review 2.  Prevalence of osteoporosis in prostate cancer survivors II: a meta-analysis of men not on androgen deprivation therapy.

Authors:  Annie-Claude M Lassemillante; Suhail A R Doi; John D Hooper; John B Prins; Olivia R L Wright
Journal:  Endocrine       Date:  2015-01-31       Impact factor: 3.633

3.  Three-dimensional trabecular bone architecture of the lumbar spine in bone metastasis from prostate cancer: comparison with degenerative sclerosis.

Authors:  Tsutomu Tamada; Teruki Sone; Yoshimasa Jo; Shigeki Imai; Yasumasa Kajihara; Masao Fukunaga
Journal:  Skeletal Radiol       Date:  2004-11-16       Impact factor: 2.199

Review 4.  Strategies for management of prostate cancer-related bone pain.

Authors:  R C Pelger; V Soerdjbalie-Maikoe; N A Hamdy
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 5.  Bone metastasis: mechanisms and therapeutic opportunities.

Authors:  Larry J Suva; Charity Washam; Richard W Nicholas; Robert J Griffin
Journal:  Nat Rev Endocrinol       Date:  2011-01-04       Impact factor: 43.330

6.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Authors:  Karim Fizazi; Michael Carducci; Matthew Smith; Ronaldo Damião; Janet Brown; Lawrence Karsh; Piotr Milecki; Neal Shore; Michael Rader; Huei Wang; Qi Jiang; Sylvia Tadros; Roger Dansey; Carsten Goessl
Journal:  Lancet       Date:  2011-02-25       Impact factor: 79.321

Review 7.  The role of bisphosphonates in the management of metastatic prostate cancer.

Authors:  M Dror Michaelson; Matthew R Smith
Journal:  Curr Oncol Rep       Date:  2003-05       Impact factor: 5.075

Review 8.  The role of the calcium-sensing receptor in bone biology and pathophysiology.

Authors:  T A Theman; M T Collins
Journal:  Curr Pharm Biotechnol       Date:  2009-04       Impact factor: 2.837

9.  Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.

Authors:  Zhong Dong; Allen D Saliganan; Hong Meng; Sanaa M Nabha; Aaron L Sabbota; Shijie Sheng; R Daniel Bonfil; Michael L Cher
Journal:  Neoplasia       Date:  2008-05       Impact factor: 5.715

10.  Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation.

Authors:  John C Araujo; Ann Poblenz; Paul Corn; Nila U Parikh; Michael W Starbuck; Jerry T Thompson; Francis Lee; Christopher J Logothetis; Bryant G Darnay
Journal:  Cancer Biol Ther       Date:  2009-11-08       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.